The landscape of Roundup (glyphosate) mass tort litigation has entered a pivotal new phase. Following critical judicial determinations on federal preemption under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), trial strategies across state and federal courtrooms are shifting rapidly away from standard label-based failure-to-warn theories toward deeper scrutiny of corporate testing practices, product formulation risks, and regulatory submission integrity.
For law firms managing large claimant inventories, adapting case strategies to these post-preemption parameters requires meticulous record organization, precise exposure verification, and proactive portfolio analysis.
Missouri Trial Shifts Focus to Product Testing and Corporate Conduct
A clear illustration of this legal evolution opened in Missouri’s 21st Judicial Circuit (St. Louis County). In Aretino et al. v. Bayer et al. (Case No. 20SL-CC03676), opening arguments marked the first Roundup cancer trial held since the U.S. Supreme Court’s landmark ruling limiting state-level, label-based failure-to-warn claims under FIFRA.
The Plaintiffs’ Post-Preemption Playbook
Representing three plaintiffs suffering from non-Hodgkin’s lymphoma (NHL), counsel adapted their strategy to navigate federal preemption boundaries by focusing on operational and scientific conduct rather than product labeling:
-
Testing Deficiencies: Alleging that Monsanto failed to perform adequate safety testing on the fully formulated Roundup product, rather than testing glyphosate in isolation.
-
Literature & Science Integrity: Presenting evidence of alleged ghostwritten scientific publications intended to influence academic and public perception.
-
Regulatory Review Flaws: Challenging the underlying data submitted during U.S. Environmental Protection Agency (EPA) regulatory evaluations.
The Defense Position
Counsel for Monsanto/Bayer continues to vigorously dispute these claims, pointing to decades of regulatory approvals and broad scientific evaluations, including the multi-year Agricultural Health Study. The defense maintains that glyphosate is non-carcinogenic and challenges the admissibility and methodology of plaintiffs’ expert witness testimony.
Is Your Roundup Inventory Ready for the Next Phase?
As litigation strategies pivot toward non-label theories, firm inventories must undergo rigorous audit and exposure documentation. Discover how Verus Mass Tort Claim Auditing Services and Mass Tort Litigation Analytics Services can help identify gaps and strengthen docket valuation.
Roundup Litigation Timeline: Key Verdicts, Preemption Battles, and Settlements
The battle over Roundup’s active ingredient, glyphosate, spans over a decade of scientific debate, multi-billion-dollar verdicts, and evolving corporate restructuring.
-
Introduction, Global Usage, and IARC Classification
- Mid-1970s–2015
- Glyphosate is introduced by Monsanto in the 1970s and becomes the world’s most widely used herbicide, accelerated by 1990s “Roundup Ready” crops. In 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) classifies glyphosate as “probably carcinogenic to humans” (Group 2A), launching the first wave of civil personal injury filings.
-
MDL Formation & Initial Landmark Bellwether Verdicts
-
-
- The federal Multidistrict Litigation (MDL No. 2741) is established in the U.S. District Court for the Northern District of California under Judge Vince Chhabria. Juries deliver massive initial awards:
- Johnson v. Monsanto (2018): California jury awards $289 million (reduced to $20.5 million on appeal).
- Hardeman v. Monsanto (2019): First federal bellwether yields $78.3 million award (affirmed at $25 million).
- Pilliod v. Monsanto (2019): California jury awards over $2 billion (reduced to $87 million).
-
$10.1B Settlement Attempt & Residential Market Phaseout
-
- 2020–2022
-
Bayer announces a $10.1 billion global settlement plan to resolve roughly 125,000 existing claims. The U.S. Supreme Court subsequently denies review of the Hardeman and Pilliod decisions, letting awards stand. Bayer announces the end of glyphosate-based residential product sales in the U.S. by 2023, shifting consumer lines to alternative active ingredients while retaining agricultural sales.
-
State Court Verdict Spikes & Mass Submissions
- 2023–2025
- Litigation moves aggressively into state court venues, yielding significant awards including a $2.25 billion Philadelphia verdict (McKivison, later reduced to $404 million) and a $2 billion verdict in Georgia, alongside targeted confidential settlements in other state jurisdictions.
-
$7.25 Billion Proposed Class Settlement Agreement
- Spring 2026
-
Bayer files a proposed nationwide $7.25 billion class settlement in Missouri state court structured over up to 21 years to resolve active and future claims. The deal faces formal opposition from multiple plaintiff law firms representing over 20,000 claimants, who contend the agreement improperly restricts plaintiff rights while favoring occupational over residential users.
-
SCOTUS Rules on FIFRA Preemption Framework
- June 2026
-
The U.S. Supreme Court issues its long-awaited decision regarding FIFRA preemption, establishing that state-law failure-to-warn claims explicitly challenging EPA-approved product labels are preempted, reshaping pleading strategies nationwide.
-
Aretino v. Bayer Opens Post-Preemption Playbook
- September 2026
- Trial opens in St. Louis County, Missouri, establishing the new post-preemption focus centered on product testing standards, EPA submission accuracy, and corporate publication practices rather than label warnings.
Essential Legal and Scientific Mechanics in Modern Roundup Claims
As dockets shift toward post-preemption arguments, mass tort litigation teams must navigate several complex evidentiary standards:
-
Specific Causation & FRE 702 (Daubert) Compliance: Demonstrating specific causation requires rigorous medical charting linking non-Hodgkin’s lymphoma diagnoses, cell subtypes, and exposure duration while withstanding strict judicial expert gatekeeping under amended Federal Rule of Evidence 702.
-
Design Defect vs. Failure-to-Warn Theories: Because direct label challenges face FIFRA preemption barriers, counsel must emphasize product formulation defects, lack of testing on whole-product mixtures, and non-label failure to warn where applicable.
-
Punitive Damages & Internal Corporate Discovery: High-value verdicts continue to hinge on internal communications, historical testing data, and proof regarding corporate knowledge of potential exposure risks.
-
Settlement Grid Matrix Validation: Evaluating inventory against complex payout grids—such as those proposed in large-scale class settlements—demands structured verification of exposure timelines, residential vs. occupational usage, and medical proof.
Streamline Your Roundup & Mass Tort Operations with Verus
Navigating shifting preemption standards, multi-jurisdictional dockets, and complicated settlement administration requires advanced technical and operational infrastructure. Verus partners with mass tort and class action law firms to streamline every phase of complex litigation:
Prepare your firm’s inventory for changing trial frameworks and global settlement opportunities. Contact Verus Today to discuss customized case support solutions.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute legal advice. Readers should consult with qualified legal counsel for advice tailored to their specific circumstances.
